← Back to Search

Diagnostic Test

HPV DNA Blood Test for Oropharyngeal Cancer (IDEA-HPV Trial)

N/A

Waitlist Available

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Palatine or lingual tonsillar asymmetry on physical exam

Neck mass present for more than 2 weeks with signs/symptoms of infection that did not resolve with antibiotic therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up long-term follow-up for up to 2 years

Awards & highlights

IDEA-HPV Trial Summary

This trial will test whether a blood test for HPV DNA can help doctors better diagnose HPV-positive oropharynx cancer.

Who is the study for?

This trial is for individuals with symptoms like a neck mass, unexplained throat pain lasting more than two weeks, or tonsillar asymmetry without signs of infection. It's not open to those who already have a confirmed diagnosis of HPV-positive oropharyngeal cancer.Check my eligibility

What is being tested?

The study is testing if a blood test for HPV DNA can help in the early detection and diagnosis of HPV-positive cancers in the throat area known as oropharynx cancer.See study design

What are the potential side effects?

Since this trial involves only a blood test for detecting HPV DNA, there are minimal side effects which may include slight pain or bruising at the needle insertion site.

IDEA-HPV Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

One of my tonsils is larger than the other.

Select...

I have had a neck lump for over 2 weeks that didn't improve with antibiotics.

Select...

I have had throat pain for over 2 weeks that antibiotics didn't help.

IDEA-HPV Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ long-term follow-up for up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~long-term follow-up for up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and long-term follow-up for up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Prevalence of circulating HPV DNA

Secondary outcome measures

HPV-OPC awareness

Impact on clinical practice

Predictive value of circulating HPV DNA

IDEA-HPV Trial Design

1Treatment groups

Experimental Treatment

Group I: Study GroupExperimental Treatment1 Intervention

All eligible participants.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,611 Previous Clinical Trials

11,470,479 Total Patients Enrolled

Media Library

Blood test for HPV DNA (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04871490 — N/A

Oropharyngeal Carcinoma Research Study Groups: Study Group

Oropharyngeal Carcinoma Clinical Trial 2023: Blood test for HPV DNA Highlights & Side Effects. Trial Name: NCT04871490 — N/A

Blood test for HPV DNA (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04871490 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent has the scope of this clinical trial been expanded?

"Affirmative. The clinicaltrials.gov website indicates that this investigation is currently recruiting members, starting from the date of its inception on March 24th 2021 and recently updated on June 8th 2022. 40 volunteers are required across a single site for successful completion of the research project."

Answered by AI

Is this clinical trial still recruiting participants?

"Clinicaltrials.gov states that this clinical trial is still in the recruitment phase, having been initially posted on March 24th 2021 and recently updated on June 8th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Improving Detection and Early Action for HPV-positive Oropharynx Cancer

Eleni M. Rettig, MD 2021. "Improving Detection and Early Action for HPV-positive Oropharynx Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04871490.